16th Apr 2019 12:06
LONDON (Alliance News) - Silence Therapeutics PLC on Tuesday reported a number of changes to its board and operational team, including its interim chair.
Andy Richards has been serving as Silence's non-executive chair since August 2018, when former Executive Chair Annalisa Jenkins departed.
Richards had previously been a non-executive director of Silence. The plan had been for him to stay until a new permanent chair joined, but he has now left.
The search for a permanent chair is ongoing, Silence said.
"Andy Richards has served on the board of Silence since 2016, first as a non-executive director and more recently as interim chair," said Chief Executive David Solomon.
"During this time, Andy has been instrumental in a implementing a bold turnaround of company strategy which has re-energised our drug-development programmes and led us to a point where we are now preparing to commence in-human trials with our lead RNAi candidate SLN124."
"I would like to thank Andy for his invaluable contribution to the company and wish him well in his future endeavours," concluded Solomon.
Elsewhere, Silence has appointed Giles Campion as its new head of research & development and chief medical officer, from the start of June.
Campion has previously had "senior" R&D roles at Novartis AG, and was also previously CMO at biotechnology firm Prosensa.
Solomon said: "On behalf of the board of Silence Therapeutics, I am delighted to welcome Giles as the new head of R&D and chief medical officer. He has an outstanding track record of leading scientific development and advancing oligonucleotide-based medicines and is therefore ideally qualified to accelerate the development of our current and future pipeline."
"Giles is a valuable addition to the management team and his expertise will help the company to deliver on its core mission of tackling the unmet medical needs of patients suffering from rare conditions."
Shares were 2.6% higher on Tuesday at a price of 58.98 pence each.
Related Shares:
SLN.L